“CLEAR” technology can revolutionize protein imaging & facilitate detection of Cancer and Neurobiological Diseases

1. At a Glance

• CLEAR (Cleavable Light-Erased Antibody Reporter) is a novel fluorescence-imaging platform that enables visualisation of an unprecedented number of proteins in the same biological sample using a single fluorophore [S1].
• Developed indigenously at JNCASR Bengaluru, an autonomous institute of DST; relevant for Sci & Tech (GS-III) as an example of frontier Indian biophysical research with clinical applications in cancer & neuro-diagnostics [S1][S2].

2. Why in the News

• PIB release dated 26 May 2026 announced the JNCASR team's CLEAR platform, published in Chemical Science (Royal Society of Chemistry) [S1].

3. Background & Evolution

• Conventional multiplexed protein imaging is limited by the small number of non-overlapping fluorophore spectral windows (~4–5), making whole-proteome spatial mapping difficult [S1].
• CLEAR replaces multi-colour imaging with iterative label–image–erase cycles using a light-cleavable probe, analogous to a chalkboard that can be wiped clean [S1].
• Built at JNCASR (established 1989, Jakkur campus, Bengaluru) under DST [S2].

4. Core Static Facts

• Full form: Cleavable Light-Erased Antibody Reporter [S1].
• Lead Scientist: Prof. Sarit S. Agasti, JNCASR [S1].
• Parent Institute: Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru — autonomous institute under Department of Science & Technology (DST), Ministry of Science & Technology [S1][S2].
• Collaborator: Indian Institute of Science (IISc), Bengaluru — immune-cell system demonstration [S1].
• Journal: Chemical Science, Royal Society of Chemistry [S1].
• Erasing trigger: a gentle pulse of 365 nm LED (UV-A) light [S1].
• Core principle: light-cleavable fluorescent tags labelled to antibodies; signal optically erased, then re-labelled in same spectral window [S1].
• Compatibility: works with live cells and delicate biological samples [S1].

5. Multi-Dimensional Analysis

Scientific / Technological - Removes spectral-overlap bottleneck — virtually unlimited multiplexing with one fluorophore [S1]. - Combines high multiplexing with speed, high spatial resolution, and live-cell compatibility, unlike existing antibody-stripping or DNA-PAINT methods [S1]. - Photo-cleavage at 365 nm avoids harsh chemical stripping that damages tissue [S1].

Health / Social - Direct relevance to cancer pathology, immunology, and neurological disorders (Alzheimer's, Parkinson's) where spatial protein organisation is diagnostic [S1]. - Enables construction of proteomic atlases of tissues — supports precision medicine [S1].

Administrative / R&D Ecosystem - Demonstrates DST's autonomous-institute model (JNCASR + IISc collaboration) delivering peer-reviewed translational science [S1][S2]. - Aligns with National Biotechnology Development Strategy and India's push for indigenous bio-imaging tools.

Economic - Single-fluorophore design lowers reagent cost and microscope complexity vs. hyperspectral/imaging-mass-cytometry platforms — potential to make high-plex pathology affordable in Indian hospitals [S1].

6. Recent Developments

• 26 May 2026 — PIB release by Ministry of Science & Technology announcing CLEAR; publication in Chemical Science (RSC) [S1].

7. Prelims Hooks

• CLEAR = Cleavable Light-Erased Antibody Reporter [S1].
• Developed by JNCASR, Bengaluru — not IISc, not CCMB [S1].
• JNCASR is autonomous under DST, not DBT [S1][S2].
• Lead researcher: Prof. Sarit S. Agasti [S1].
• Uses 365 nm LED light to erase fluorescence [S1].
• Published in Chemical Science (Royal Society of Chemistry) [S1].
• Uses a single fluorophore for multiplexed imaging [S1].
• IISc Bengaluru collaborated on immune-cell system validation [S1].
• JNCASR established 1989, campus at Jakkur, Bengaluru [S2].
• Target diseases: cancers, immunological disorders, neurological disorders [S1].
• Method works on live cells [S1].
• Mechanism analogy: chalkboard — label, image, erase, relabel [S1].

8. Mains Relevance

• GS-III — Science & Technology: "Developments and their applications and effects in everyday life" / Indigenous technology, biotech.
• GS-II — Health (diagnostics access) — secondary.
• Plausible question stems: 1. "Indigenous innovations in bio-imaging are critical for affordable precision medicine in India. Discuss with reference to recent advances such as CLEAR technology." 2. "Examine the role of DST-funded autonomous institutes in translating frontier research into clinical applications." 3. "How can advances in multiplexed protein imaging transform cancer diagnostics in India?"

9. Related Topics to Study Next

• JNCASR & DST autonomous institutes — institutional ecosystem.
• National Biotechnology Development Strategy / BIRAC — biotech funding pipeline.
• CRISPR & Centre of Excellence for CRISPR Innovation (CoE-CIT) — parallel JNCASR/DBT effort [S2].
• Human Cell Atlas / Spatial Transcriptomics — global proteomic-mapping context.
• Anusandhan National Research Foundation (ANRF) — new R&D funding architecture.
• Fluorescence microscopy & Nobel Prize 2014 (super-resolution) — foundational science.
• National Mission on Quantum Tech & Interdisciplinary Cyber-Physical Systems — frontier-science missions.
• AYUSH / ICMR cancer registries — diagnostic-policy linkage.

10. Common Errors / Trap Areas

• JNCASR is under DST, NOT DBT or CSIR — easy confusion [S1][S2].
• Light source is 365 nm (UV-A LED), not laser, not visible light [S1].
• CLEAR is an imaging platform, not a therapy or drug.
• Lead author is at JNCASR; IISc is a collaborator, not the originator [S1].
• Published in Chemical Science (RSC) — not Nature or Science.

11. Sources

• [S1] "CLEAR technology can revolutionize protein imaging…" — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2265421 — (tier 1)
• [S2] "Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore" — https://dst.gov.in/autonomousstinstitutions/jawaharlal-nehru-centre-advanced-scientific-research-bangalore — (tier 1)